The FDA cleared Merck’s first oral PCSK9 cholesterol drug, Lipfendra (enlicitide), marking a major shift for patients who need deeper LDL lowering than statins alone. The once-daily pill reduces LDL levels to targets far below typical statin ranges, with trial data showing reductions of up to about 60% and a side-effect profile described as comparable to placebo. The approval follows new cholesterol guideline updates from the American Heart Association and the American College of Cardiology in March, which pushed more aggressive LDL targets for higher-risk patients. Merck is also running studies designed to test whether the therapy can reduce heart attacks and strokes. For biotech stakeholders, the clearance also underscores continuing regulatory willingness to broaden cardiovascular prevention toolkits beyond injectable biologics—potentially reshaping competitive dynamics across lipid-lowering and adjacent cardiometabolic drug classes.